279
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis

, , , , , , , & show all
Pages 807-820 | Received 15 Feb 2023, Accepted 20 May 2023, Published online: 02 Jun 2023

Figures & data

Figure 1 Flow diagram of patient enrollment.

Abbreviations: DEB-TACE, drug-eluting bead transcatheter arterial chemoembolization; TACE, transcatheter arterial chemoembolization; cTACE, conventional transcatheter arterial chemoembolization; HAIC, hepatic artery infusion chemotherapy; LEN, lenvatinib; ICIs, immune checkpoint inhibitors; ORR, objective response rate; PFS, progression-free survival; mRECIST, modified Response Evaluation Criteria in Solid Tumors.
Figure 1 Flow diagram of patient enrollment.

Table 1 Baseline Characteristics in 35 Patients

Figure 2 Kaplan-Meier analyses of progression-free survival according to treatment group.

Figure 2 Kaplan-Meier analyses of progression-free survival according to treatment group.

Table 2 Radiological Responses According to the mRECIST Criteria and Clinical Efficacy

Table 3 Tumor Responses According to the mRECIST Criteria for Different BCLC Stage

Figure 3 (a) Waterfall chart of target tumor response produced by investigator using the mRECIST criteria. (b) Tumor responses according to the mRECIST criteria for different BCLC stage.

Abbreviations: mRECIST, modified Response Evaluation Criteria in Solid Tumors; BCLC, Barcelona Clinic Liver Cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
Figure 3 (a) Waterfall chart of target tumor response produced by investigator using the mRECIST criteria. (b) Tumor responses according to the mRECIST criteria for different BCLC stage.

Table 4 Treatment-Related Adverse Events [n (%)]